Bio Break: Laboratory Developed Tests vs. In Vitro Diagnostics

Resources

Bio Break: Laboratory Developed Tests vs. In Vitro Diagnostics

Sector: Diagnostics
Topic: Bio Break

In this episode of Bio Break, Joris van der Heijden and Nick Allan dive into the FDA’s new regulations surrounding Laboratory Developed Tests (LDTs) and their impact on the medical device industry. As LDTs grow in complexity, including applications like genetic testing and AI-driven diagnostics, these regulatory changes mark a significant shift for laboratories, developers, and healthcare providers.

Nick, drawing on his experience with medical device development, explains the critical distinctions between LDTs and In Vitro Diagnostics (IVDs). He provides insights into why these changes are happening and what they mean for developers working to bring innovative diagnostic tools to market.

Key takeaways from the episode include:

  • Understanding the Difference: LDTs are clinically validated tests performed in CLIA-approved labs but do not require FDA regulatory clearance, unlike IVDs, which are classified as medical devices.
  • The Shift in Regulation: The FDA is transitioning from selective enforcement to increased scrutiny due to the growing complexity and impact of LDTs, such as cancer diagnostics and genetic testing.
  • Implications for Developers: Nick explores how the new regulations add layers of oversight but also improve the safety, accuracy, and reliability of tests with far-reaching implications for patient care.

Joris and Nick discuss the broader industry impacts, including the challenges and opportunities presented by these regulatory changes. While some pushback is expected, they highlight how these steps are ultimately beneficial for innovation and patient outcomes, ensuring that advanced diagnostics meet higher standards of clinical utility and reliability.

This episode is essential viewing for medical device developers, diagnostic innovators, and healthcare professionals navigating the evolving regulatory landscape. Gain a clear understanding of how the FDA’s increased involvement in LDTs is shaping the future of diagnostics and how to stay ahead in this rapidly changing environment.

Laboratory Developed Tests vs. In Vitro Diagnostics

YouTube video thumbnail

Read our article on the impact of FDA Laboratory Developed Tests 2024 Policy update to its regulatory approach for in vitro diagnostic products (IVDs), including laboratory developed tests (LDTs). 

A vial of orange liquid with a radiation symbol and a syringe sit on a reflective metal surface in front of a large medical imaging machine. The overlay text reads: "Radioactive. On Purpose?" in bold black font on a white rounded background.

Radiopharmaceutical Device Development Explained

Radiopharmaceutical device development is gaining momentum as medical teams explore new frontiers in diagnostic imaging and cancer treatment.

Surgeon practicing on a surgical simulator during a medical training session in a clinical environment

The importance of a user-centered design approach to training: A case study

The simplest and least expensive way to train users of medical devices is to ask them study the Instructions for Use (IFU) beforehand.

An iron lung on the left and a modern medical ventilator on the right, shown against a plain white background. A red arrow points from the iron lung to the ventilator. Bold overlay text reads: ‘Then vs. Now’ in white font on a black background.

Iron Lung Innovation and Ventilator History

In this MedDevice by Design episode, Ariana Wilson and Mark Drlik take us back in time to explore iron lung innovation during the polio epidemic of the 1920s.

Visual metaphor for transforming ideas into tangible prototypes through rapid innovation in medical device development

Touch It to Believe It: Cost-Efficient, Tangible Prototypes That Impress Users, Boards and Investors.

In the complex world of medical device development, creating effective prototypes is more than just a creative exercise, it’s a regulatory necessity and a strategic imperative.